Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this study is to develop a registry with safety and efficacy data on the use of etanercept in clinical practice in Taiwan.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| 1 | Non-intervention |
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Safety: Proportion of patients discontinued from etanercept as a result of an adverse event by Week 24, laboratory exam findings, incidence of adverse events, and vital signs and physical exam findings. Efficacy: Disease Activity Score 28 at week 20. | 24 weeks |
| Measure | Description | Time Frame |
|---|---|---|
| Global health assessment; Erythrocyte sedimentation rate; Number of swollen or tender joints; C-reactive protein; Proportion of patients having worsened DAS 28 and components of DAS 28,CRP than baseline; Etanercept approval-lag time. | 24 weeks |
Not provided
Inclusion Criteria:
Main Inclusion Criteria: 1) Male or female patients aged > 20 years; 2) Patients who have already been selected and approved under the Taiwan National Health Insurance Program to receive 24 weeks of etanercept for rheumatoid arthritis. Main
Exclusion Criteria:
Exclusion Criteria: None
Not provided
Not provided
Not provided
clinic
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Pfizer CT.gov Call Center | Pfizer | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Pfizer Investigational Site | Changhua | Changhua County | 500 | Taiwan | ||
| Pfizer Investigational Site |
Not provided
| Label | URL |
|---|---|
| To obtain contact information for a study center near you, click here. | View source |
Not provided
Not provided
Not provided
Not provided
Not provided
| Changhua |
| Changhua |
| 500 |
| Taiwan |
| Pfizer Investigational Site | Lukang Zhen | Changhua | 50544 | Taiwan |
| Pfizer Investigational Site | Dalin | Chia-Yi | 622 | Taiwan |
| Pfizer Investigational Site | Putz | Chiayi | 61363 | Taiwan |
| Pfizer Investigational Site | Kaohsiung City | Kaohsiung | 807 | Taiwan |
| Pfizer Investigational Site | Kaohsiung City | Kaohsiung | 81346 | Taiwan |
| Pfizer Investigational Site | Niao Sung Hsiang | Kaohsiung | 83301 | Taiwan |
| Pfizer Investigational Site | Keelung | Keelung | 204 | Taiwan |
| Pfizer Investigational Site | Taichung | Taichung | 402 | Taiwan |
| Pfizer Investigational Site | Taichung | Taichung | 427 | Taiwan |
| Pfizer Investigational Site | Taipei | Taipei | 14409 | Taiwan |
| Pfizer Investigational Site | Taipei TOC | Taiwan | 100 | Taiwan |
| Pfizer Investigational Site | Guishanli | Taoyuan | 33305 | Taiwan |
| Pfizer Investigational Site | Taoyuan | Taoyuan | 330 | Taiwan |
| Pfizer Investigational Site | Hualien City | 97002 | Taiwan |
| Pfizer Investigational Site | Taichung | 407 | Taiwan |
| Pfizer Investigational Site | Tainan | 70428 | Taiwan |
| Pfizer Investigational Site | Taipei | 10630 | Taiwan |
| Pfizer Investigational Site | Taipei | 11042 | Taiwan |
| Pfizer Investigational Site | Taipei | 116 | Taiwan |
| Pfizer Investigational Site | Taipei | 220 | Taiwan |
| Pfizer Investigational Site | Taoyuan | 333 | Taiwan |
| ID | Term |
|---|---|
| D001172 | Arthritis, Rheumatoid |
| ID | Term |
|---|---|
| D001168 | Arthritis |
| D007592 | Joint Diseases |
| D009140 | Musculoskeletal Diseases |
| D012216 | Rheumatic Diseases |
| D003240 | Connective Tissue Diseases |
| D017437 | Skin and Connective Tissue Diseases |
| D001327 | Autoimmune Diseases |
| D007154 | Immune System Diseases |
Not provided
Not provided